Esperion Therapeutics Annual Income Statement (NASDAQ:ESPR)

Add to My Stocks
$36.69 $0.69 (1.85%) ESPR stock closing price Apr 21, 2017 (Closing)

Looking at financial statements, along with the Esperion Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis.   The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The Esperion Therapeutics profit and loss statement for 2016 shows a profit of $-74.97M. Profits have reduced from $-49.78M YoY. Apart from this an investor should also check Esperion Therapeutics assets and Esperion Therapeutics free cash flow. Esperion Therapeutics revenue for 2016 is $/NAN/. View revenue and profit details for latest and last 10 financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011
Esperion Therapeutics Net Sales or Revenues
------
Cost Of Goods Sold (COGS)------
Esperion Therapeutics Gross Profit
------
Research & Development Expense57.86M29.8M25.3M16.01M7.99M7.8M
Selling General & Admin Expense18.28M20.23M10.92M6.74M2.2M2.35M
Income Before Depreciation Depletion Amortization-76.15M-50.04M-36.22M-22.75M-10.2M-10.16M
Depreciation Depletion Amortization------
Non Operating Income1.54M0.77M0.11M-2.39M0.03M-0.07M
Interest Expense0.37M0.52M0.27M0.93M1.48M0.57M
Esperion Therapeutics Pretax Income
-74.97M-49.78M-36.37M-26.08M-11.65M-10.81M
Provision for Income Taxes------
Minority Interest------
Investment Gains Losses------
Other Income------
Income Before Extraordinaries & Disc Operations-74.97M-49.78M-36.37M-26.08M-11.65M-10.81M
Extraordinary Items & Discontinued Operations------
Esperion Therapeutics Net Income (Profit/Loss)
-74.97M-49.78M-36.37M-26.08M-11.65M-10.81M
Average Shares used to compute Diluted EPS22.55M22.02M16.37M7.89M3.76M-
Average Shares used to compute Basic EPS22.55M22.02M16.37M7.89M3.76M-
Income Before Nonrecurring Items-74.98M-49.78M-36.38M-23.42M-11.74M-
Income from Nonrecurring Items----2.59M--
Esperion Therapeutics Earnings Per Share Basic Net
-3.33-2.26-2.22-3.31-3.13-
Esperion Therapeutics Earnings Per Share Diluted Net
-3.33-2.26-2.22-3.31-3.13-
EPS Diluted Before Nonrecurring Items-3.33-2.26-2.22-2.98-3.13-
Preferred Dividends Acc Pd------
Dividends Common------
Dividend Per Share Common------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Income statement for another ticker

Esperion Therapeutics stock analysis involves checking at least a few of the important things like:
  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. ESPR stock had a healthy bottom line growth.
The income statement is also called the profit and loss statement. Apart from the income statement, one can check the Esperion Therapeutics historical stock prices to check how the price has moved with time. .